肝硬化患者血细胞钙、镁含量的临床观察  

Study on cellular and serum concentration of calcium and magnesium in peripheral blood cells of cirrhosis

作　　者：王方剑[1] 曹洁[2] 马丽萍[1] 金镇勋[1] 

机构地区：[1]第四军医大学吉林军医学院附属解放军第465医院消化内科,吉林132013 [2]第四军医大学吉林军医学院附属解放军第465医院特诊科,吉林132013

出　　处：《中华肝脏病杂志》2004年第3期144-147,共4页Chinese Journal of Hepatology

摘　　要：目的 观察肝硬化时细胞内钙、镁含量的改变及其临床意义。 方法 测定50例肝硬化失代偿期(A组)、3 5例代偿期(B组)患者的血清钙(SCa)、血小板钙(PCa)、单个核白细胞钙(MNCCa)、多形核白细胞钙(PMNCa)、红细胞钙(RCa)和血清镁(SMg)、血小板镁(PMg)、单个核白细胞镁(MNCMg)、多形核白细胞镁(PMNMg)、红细胞镁(RMg)。以35名健康人为对照组。 结果 A组和B组SCa、SMg显著低于对照组。A组MNCCa和PMNCa(μmol/109)为4.76±1.91和7.56±2.88、RCa和RMg(mmol/L)为0.66±0.13和2.02±0.76、PMg(μmol/1 011)5.53±2.25、MNCMg和PMNMg(μmol/109)为6.64±3.53和10.12±4.32。B组MNCCa和PMNCa(μmol/109)为5.34±2.41和8.32±2.34、RCa和RMg(mmol/L)为0.67±0.11和2.21±0.74、PMg(μmol/1011)5.55±2.67、MNCMg和PMNMg(μmol/109)为6.56±3.44和10.95±4.45;对照组MNCCa和PMNCa(μmol/109)6.86±2.02、9.89±3.23、RCa和RMg(mmol/L)0.72±0.10和2.74+0.92、PMg(μmol/1011)(7.43±2.78)、MNCMg和PMNMg(μmol/109)为8.68±4.13和13.96±5.76,A组和B组与对照组比较t=4.88～2.00,P<0.01或0.05。肝性脑病组细胞内外镁显著低于非肝性脑病组t=2.30～2.01,P缸均<0.05,PCa显著高于非肝性腑病组,t=2.02,P<0.0 5。4种血细咆镁?Objective To study on the changes of intracellular calcium and magnesium in cirrhosis and its clinical significance. Methods The calcium and magnesium were determined in serum (SCa, SMg), platelets (PCa, PMg), mononuclear cells (MNCCa, MNCMg), polymorpho-nuclearcells (PMNCa, PMNMg) and erythrocytes (RCa, RMg) of 50 patients with uncompensative cirrhosis ( group A) and of 35 patients with compensative cirrhosis (group B). 35 health persons were the control group. Results The SCa and SMg of group A were lower significantly than those of both group B and control group (all Ps<0.01). The MNCCa, PMNCa, RCa, PMg, MNCMg, PMNMg, RMg of group A [(4.76 ±1.91) μmol/109, (7.56±2.88)μmol/109, (0.66±0.13)mmol/L, (5.53±2.25) μmol/1011, (6.64±3.53) μmol/109, (10.12±4.32) μmol/109, (2.02±0.76) mmol/L] and those of group B [(5.34±t 2.41) μmol/109, (8.32±2.34) μmol/109, (0.67±0.11) mmol/L, (5.55±2.67) μmol/1011, (6.56±3.44) μmol/109, (10.95±4.45) μmol/109, (2.21±0.74) mmol/L] were lower significantly than those of control group [(6.86±2.02) μmol/109, (9.89±3.23) μmol/109, (0,72±0.10) mmol/L, (7.43±2.78) μmol/1011, (8.68± 4.1) μmol/109, (13.96±5.76) μmol/109, (2.74±0.92) mmol/L]; ( (group A vs. control group) = 4.88, 3.48, 2.31, 3.45, 2.46, 3.52, 4.00. P < 0.01, 0.01, 0.05, 0.01, 0.02, 0.01, 0.01; t (group B vs. control group) = 2.87, 2.34, 2.00, 2.89, 2.33, 2.45, 2.65, P < 0.01, 0.05, 0.05, 0.01, 0.05, 0.02, 0.02. The PCa of the patients with hepatic encephalopathy was higher, the SMg, PMg. MNCMg, PMNMg and RMg were lower than those of the patients without hepatic encephalopathy significantly. The SCa. SMg, PMg, MNCMg, PMNMg and RMg of the patients in Child stage C were lower significantly than those of the patients in Child stage B. There were no significant differences of PCa, MNCCa, PMNCa and RCa between Child stage C and Child stage B. There were no significant differences of SCa, MNCCa, PMNCa and RCa between the patients with and without hepatic encephalopathy. The ratios of PCa/SCa, MNCCa/S

关 键 词：肝硬化 钙 镁 失代偿期 测定 

分 类 号：R575.2[医药卫生—消化系统]